Adjusted Supplementary Information to the Annual Report 2019
Valby, Denmark, 05 January 2021 - H. Lundbeck A/S (Lundbeck) announced the publication of Adjusted Supplementary Information to the Annual Report 2019 as required by the Danish Business Authority (“Erhvervsstyrelsen”). Lundbeck communicated on 27 November 2020, that the Danish Business Authority had required Lundbeck to conduct an impairment test of Rexulti product rights for 2017. The impairment test lead to a reversal of an impairment loss on Rexulti (brexpiprazole) of DKK 3,766 million, net of amortization as of 31 December 2017. This generates an increase in intangible assets for